Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.

ABSTRACT:

Background

We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults.

Methods

HER-MES was a 24-week, randomised, double-blind, double-dummy, controlled trial conducted in 82 sites in Germany. Patients with ≥4 migraine days per month and naïve to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140 mg/month) plus topiramate placebo (erenumab group) or oral topiramate at the individual dose with optimal efficacy (50-100 mg/day) plus erenumab placebo (topiramate group).The primary endpoint was medication discontinuation due to an adverse event during the double-blind phase. The proportion of patients that achieved ≥50% reduc

SUBMITTER: Reuter U 

PROVIDER: S-EPMC8793299 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature